Evaluation of proactive therapeutic drug monitoring application in infliximab users in ulcerative colitis

Giovelli, Gabriela Maria Henz; Cassol, Ornella Sari; Lubini, Marcio; Costa, Angelina Dantas; Gaviraghi, Édina; Martini, Laura de Cezaro.
J. coloproctol. (Rio J., Impr.) ; 43(4): 286-291, Oct.-Dec. 2023. tab
Artigo em Inglês | LILACS | ID: biblio-1528937

Documentos relacionados

  1. Therapeutic drug monitoring in inflammatory bowel disease reduces unnecessary use of infliximab with substantial associated cost-savings.
  2. Therapeutic Drug Monitoring of Antibody Drugs.
  3. Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study.
  4. Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis.
  5. Outcomes out to 12 months after sequential use of high-dose tofacitinib following infliximab in acute severe ulcerative colitis.
  6. Four-year review of New Zealand laboratory infliximab and adalimumab concentration results indicating potential for improved dosing.
  7. Therapeutic Drug Monitoring Can Guide the Intravenous-to-Subcutaneous Switch of Infliximab and Vedolizumab: A Simulation Study.
  8. Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.
  9. Using Therapeutic Drug Monitoring to Identify Variable Infliximab Metabolism in an Individual Patient With Ulcerative Colitis.
  10. [Current and prospective biologics and small molecules in the treatment of inflammatory bowel diseases].